Evelo Biosciences Analyst Ratings
Evelo Biosciences Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/18/2023 | — | TD Cowen | Downgrades | Outperform → Market Perform | |
| 07/26/2023 | 669.23% | Morgan Stanley | $2 → $10 | Maintains | Equal-Weight |
| 02/15/2023 | 53.85% | Morgan Stanley | $4 → $2 | Maintains | Equal-Weight |
| 11/16/2022 | 92.31% | Chardan Capital | → $2.5 | Downgrades | Buy → Neutral |
| 09/09/2022 | 207.69% | Morgan Stanley | $5 → $4 | Maintains | Equal-Weight |
| 08/24/2022 | 284.62% | Morgan Stanley | $6 → $5 | Maintains | Equal-Weight |
| 08/15/2022 | 284.62% | Chardan Capital | $12 → $5 | Maintains | Buy |
| 11/02/2021 | 3092.31% | JMP Securities | $44 → $41.5 | Maintains | Market Outperform |
| 11/01/2021 | 823.08% | Chardan Capital | → $12 | Upgrades | Neutral → Buy |
| 06/23/2021 | 2823.08% | JMP Securities | $36 → $38 | Maintains | Market Outperform |
| 06/23/2021 | 2053.85% | Cantor Fitzgerald | → $28 | Initiates Coverage On | → Overweight |
| 05/03/2021 | 900% | Morgan Stanley | $14 → $13 | Maintains | Equal-Weight |
| 04/12/2021 | 1284.62% | Jefferies | $11 → $18 | Upgrades | Hold → Buy |
| 01/19/2021 | 976.92% | Morgan Stanley | $6 → $14 | Maintains | Equal-Weight |
| 12/23/2020 | 1976.92% | JMP Securities | → $27 | Initiates Coverage On | → Outperform |
| 11/11/2020 | 361.54% | Morgan Stanley | $8 → $6 | Maintains | Equal-Weight |
| 05/21/2020 | 515.38% | Morgan Stanley | → $8 | Downgrades | Overweight → Equal-Weight |
| 05/12/2020 | 1515.38% | BMO Capital | $24 → $21 | Maintains | Outperform |
| 05/12/2020 | 361.54% | Jefferies | $18 → $6 | Downgrades | Buy → Hold |
| 04/30/2019 | 1284.62% | Jefferies | → $18 | Initiates Coverage On | → Buy |
| 01/29/2019 | 669.23% | Chardan Capital | → $10 | Initiates Coverage On | → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 2023 年 10 月 18 日 | — | TD Cowen | 降級 | 跑贏大盤 → 市場表現 | |
| 07/26/2023 | 669.23% | 摩根士丹利 | 2 美元 → 10 美元 | 維護 | 重量相等 |
| 02/15/2023 | 53.85% | 摩根士丹利 | 4 美元 → 2 美元 | 維護 | 重量相等 |
| 11/16/2022 | 92.31% | 查丹資本 | → 2.5 美元 | 降級 | 買入 → 中性 |
| 09/09/2022 | 207.69% | 摩根士丹利 | 5 美元 → 4 美元 | 維護 | 重量相等 |
| 2022 年 8 月 24 日 | 284.62% | 摩根士丹利 | 6 美元 → 5 美元 | 維護 | 重量相等 |
| 08/15/2022 | 284.62% | 查丹資本 | 12 美元 → 5 美元 | 維護 | 買 |
| 11/02/2021 | 3092.31% | JMP 證券 | 44 美元 → 41.5 美元 | 維護 | 市場表現跑贏大盤 |
| 11/01/2021 | 823.08% | 查丹資本 | → 12 美元 | 升級 | 中性 → 買入 |
| 06/23/2021 | 2823.08% | JMP 證券 | 36 美元 → 38 美元 | 維護 | 市場表現跑贏大盤 |
| 06/23/2021 | 2053.85% | 坎託·菲茨傑拉德 | → 28 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 05/03/2021 | 900% | 摩根士丹利 | 14 美元 → 13 美元 | 維護 | 重量相等 |
| 2021 年 12 月 4 日 | 1284.62% | 傑富瑞集團 | 11 美元 → 18 美元 | 升級 | 持有 → 買入 |
| 01/19/2021 | 976.92% | 摩根士丹利 | 6 美元 → 14 美元 | 維護 | 重量相等 |
| 12/23/2020 | 1976.92% | JMP 證券 | → 27 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 11/11/2020 | 361.54% | 摩根士丹利 | 8 美元 → 6 美元 | 維護 | 重量相等 |
| 05/21/2020 | 515.38% | 摩根士丹利 | → 8 美元 | 降級 | 超重 → 重量相等 |
| 05/12/2020 | 1515.38% | BMO Capital | 24 美元 → 21 美元 | 維護 | 跑贏大盤 |
| 05/12/2020 | 361.54% | 傑富瑞集團 | 18 美元 → 6 美元 | 降級 | 買入 → 持有 |
| 2019 年 4 月 30 日 | 1284.62% | 傑富瑞集團 | → 18 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2019 年 1 月 29 日 | 669.23% | 查丹資本 | → 10 美元 | 啓動覆蓋範圍開啓 | → 中立 |
What is the target price for Evelo Biosciences (EVLO)?
Evelo Biosciences（EVLO）的目標價格是多少？
The latest price target for Evelo Biosciences (NASDAQ: EVLO) was reported by TD Cowen on October 18, 2023. The analyst firm set a price target for $0.00 expecting EVLO to fall to within 12 months (a possible -100.00% downside). 4 analyst firms have reported ratings in the last year.
道明考恩於2023年10月18日公佈了Evelo Biosciences（納斯達克股票代碼：EVLO）的最新目標股價。該分析公司將目標股價定爲0.00美元，預計EVLO將在12個月內跌至-100.00％（可能下跌-100.00％）。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for Evelo Biosciences (EVLO)?
Evelo Biosciences（EVLO）的最新分析師評級是多少？
The latest analyst rating for Evelo Biosciences (NASDAQ: EVLO) was provided by TD Cowen, and Evelo Biosciences downgraded their market perform rating.
Evelo Biosciences（納斯達克股票代碼：EVLO）的最新分析師評級由道明考恩提供，Evelo Biosciences下調了其市場表現評級。
When is the next analyst rating going to be posted or updated for Evelo Biosciences (EVLO)?
Evelo Biosciences（EVLO）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evelo Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evelo Biosciences was filed on October 18, 2023 so you should expect the next rating to be made available sometime around October 18, 2024.
分析師在進行了廣泛的研究後得出了股票評級，包括閱讀公開財務報表、與Evelo Biosciences的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Evelo Biosciences的最後一次評級是在2023年10月18日提交的，因此你應該預計下一個評級將在2024年10月18日左右公佈。
Is the Analyst Rating Evelo Biosciences (EVLO) correct?
分析師對 Evelo Biosciences (EVLO) 的評級正確嗎？
While ratings are subjective and will change, the latest Evelo Biosciences (EVLO) rating was a downgraded with a price target of $0.00 to $0.00. The current price Evelo Biosciences (EVLO) is trading at is $1.30, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Evelo Biosciences（EVLO）評級已下調，目標股價爲0.00美元至0.00美元。Evelo Biosciences（EVLO）目前的交易價格爲1.30美元，超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。